Torpharm Ticlopidine Ad To Run In August JAMA; Educational Materials Cited
Executive Summary
Apotex' U.S. subsidiary Torpharm will run an advertisement in the August issue of the Journal of the American Medical Association referencing its safety education program for the first generic version of ticlopidine (Roche's Ticlid). Torpharm's ticlopidine cleared FDA July 1 with a therapeutically equivalent "AB" rating.
You may also be interested in...
Sanofi-Synthelabo/Bristol Plan Avapro Heart Failure Program
Sanofi-Synthelabo and co-marketing partner Bristol-Myers Squibb are discussing Phase III protocols in cardiac insufficiency for the angiotensin II inhibitor Avapro (irbesartan), Sanofi-Synthelabo COO Herve Guerin told an analysts meeting in London Sept. 2.
Sanofi-Synthelabo/Bristol Plan Avapro Heart Failure Program
Sanofi-Synthelabo and co-marketing partner Bristol-Myers Squibb are discussing Phase III protocols in cardiac insufficiency for the angiotensin II inhibitor Avapro (irbesartan), Sanofi-Synthelabo COO Herve Guerin told an analysts meeting in London Sept. 2.
Dismissal Of Teva Suit Triggered Ticlopidine 180-Days, Appeals Court Rules
Torpharm's 180-day ticlopidine exclusivity was triggered by the June 1998 dismissal of Teva's declaratory judgment action against Roche in California federal court, the D.C. federal appeals court ruled July 20.